4WCU
PDE4 complexed with inhibitor
Summary for 4WCU
| Entry DOI | 10.2210/pdb4wcu/pdb |
| Related | 4W1O |
| Descriptor | cAMP-specific 3',5'-cyclic phosphodiesterase 4D, N-benzyl-2-{6-[(3,5-dichloropyridin-4-yl)acetyl]-2,3-dimethoxyphenoxy}acetamide, ZINC ION, ... (5 entities in total) |
| Functional Keywords | inhibitor, complex, pde4d, hydrolase |
| Biological source | Homo sapiens (Human) |
| Cellular location | Apical cell membrane: Q08499 |
| Total number of polymer chains | 4 |
| Total formula weight | 167442.72 |
| Authors | Sorensen, M.D. (deposition date: 2014-09-05, release date: 2014-10-08, Last modification date: 2024-05-08) |
| Primary citation | Felding, J.,Sorensen, M.D.,Poulsen, T.D.,Larsen, J.,Andersson, C.,Refer, P.,Engell, K.,Ladefoged, L.G.,Thormann, T.,Vinggaard, A.M.,Hegardt, P.,Sohoel, A.,Nielsen, S.F. Discovery and Early Clinical Development of 2-{6-[2-(3,5-Dichloro-4-pyridyl)acetyl]-2,3-dimethoxyphenoxy}-N-propylacetamide (LEO 29102), a Soft-Drug Inhibitor of Phosphodiesterase 4 for Topical Treatment of Atopic Dermatitis. J. Med. Chem., 57:5893-5903, 2014 Cited by PubMed Abstract: Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades. However, only roflumilast has received FDA approval. One key challenge has been the low therapeutic window observed in the clinic for PDE4 inhibitors, primarily due to PDE4 mediated side effects. Here we describe our approach to circumvent this issue by applying a soft-drug concept in the design of a topically acting PDE4 inhibitor for treatment of dermatological diseases. We used a fast follower approach, starting from piclamilast. In particular, simultaneous introduction of 2'-alkoxy substituents and changing an amide to a keto linker proved to be beneficial when designing potential soft-drug candidates. This effort culminated in identification of LEO 29102 (20), a potent, selective, and soft-drug PDE4 inhibitor with properties suitable for patient-friendly formulations giving efficient drug delivery to the skin. Compound 20 has reached phase 2 and demonstrated clinically relevant efficacy in the treatment of atopic dermatitis. PubMed: 24984230DOI: 10.1021/jm500378a PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.35 Å) |
Structure validation
Download full validation report
